Abstract
Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing everyother- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
Keywords: Statins, intolerance, muscle symptoms, transaminases, creatine kinase, new-onset diabetes, side effects, ezetimibe, proprotein convertase subtilisin kexin 9 inhibitors, non-statin lipid-lowering drugs.
Current Vascular Pharmacology
Title:Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Volume: 14 Issue: 6
Author(s): Niki Katsiki, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Statins, intolerance, muscle symptoms, transaminases, creatine kinase, new-onset diabetes, side effects, ezetimibe, proprotein convertase subtilisin kexin 9 inhibitors, non-statin lipid-lowering drugs.
Abstract: Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing everyother- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
Export Options
About this article
Cite this article as:
Katsiki Niki, Athyros G. Vasilios and Karagiannis Asterios, Exploring the Management of Statin Intolerant Patients: 2016 and Beyond, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160226150028
DOI https://dx.doi.org/10.2174/1570161114666160226150028 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Cycle Dependent Regulation of Intracellular Calcium Concentration in Vascular Smooth Muscle Cells: A Potential Target for Drug Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Nutritional Antioxidants Mechanisms of Action, Analyses of Activities and Medical Applications
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Effects of Huangkui Capsule on the Expression of SPARC in the Kidney Tissue of a Rat Model with Diabetic Nephropathy
Current Gene Therapy CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics New Class of Pyrimidinesulfamoyl Containing Pyrazole and Pyrrole Derivatives and Their Antioxidant Activity
Letters in Organic Chemistry Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?
Recent Patents on Cardiovascular Drug Discovery The Real Code of Leonardo da Vinci
Current Cardiology Reviews Calcium Channel Blockers in the Management of Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry